Columnar Cell Change of the Breast: What It Means

Columnar cell change is a benign finding in breast tissue where the normal low, cube-shaped cells lining the milk-producing units are replaced by taller, column-shaped cells. It shows up on a pathology report after a breast biopsy and, on its own, does not require surgery or additional treatment. The finding sits at the mildest end of a family of related changes pathologists group under “columnar cell lesions,” and understanding where it falls on that spectrum is the key to knowing what it means for you.

What Columnar Cell Change Looks Like Under the Microscope

The milk-producing part of the breast is organized into structures called terminal duct lobular units, which are clusters of tiny sacs (acini) connected by small ducts. Normally, these sacs are lined by a single neat layer of low, roughly cube-shaped epithelial cells. In columnar cell change, those cells are replaced by taller, narrower cells that look like tiny columns standing side by side. The sacs themselves are often slightly stretched or dilated, and the tops of the columnar cells frequently have small projections called apical snouts that release secretions into the space inside the sac.¹

A pathologist looking at a biopsy slide can typically identify columnar cell change by those features: a single layer (sometimes two) of tall columnar cells, with no piling up or crowding. When the cells do start to pile up into multiple layers, the finding is reclassified as columnar cell hyperplasia. And when the cells show certain abnormal nuclear features on top of that layering, it gets a third label: flat epithelial atypia.² These three categories form the columnar cell lesion spectrum, and the distinctions between them matter because the management recommendations differ.

The Columnar Cell Lesion Spectrum

Pathologists classify columnar cell lesions into three tiers based on what the cells look like and how many layers thick they are:

Columnar cell change (CCC): One or two layers of columnar cells with no unusual nuclear features. This is the simplest form and is considered benign.
Columnar cell hyperplasia (CCH): Multiple layers of columnar cells, sometimes with small tufts projecting into the lumen, but still without atypical nuclei. Also generally managed as benign.
Flat epithelial atypia (FEA): Columnar cells that show cytologic atypia, meaning the nuclei look rounder, more uniform, and slightly abnormal compared to the cells in CCC or CCH. This category draws more clinical attention.

One study that used precise measurements of nuclear shape found that cells in flat epithelial atypia had significantly rounder nuclei than cells in columnar cell change or hyperplasia. Within the FEA group, cases that were later associated with a cancer had even rounder nuclei than FEA cases without cancer.³ That kind of subtle shape difference is one reason this spectrum can be hard for pathologists to classify consistently, a problem we’ll return to later.

How Columnar Cell Change Gets Found

Most people never know they have columnar cell change unless a biopsy is done for another reason, usually because a mammogram flagged something suspicious. The most common mammographic trigger is microcalcifications, tiny calcium deposits that show up as small bright specks on imaging. Columnar cell lesions tend to produce a particular type of calcification: psammomatous bodies and calcified secretions that collect inside the dilated acini.⁴

The shift from older film-based mammography to digital mammography has made a noticeable difference here. Digital systems are better at detecting microcalcifications, and as a result, more biopsies are performed for calcifications alone. That in turn means more columnar cell lesions are being discovered. In one study comparing the two eras, columnar cell lesions were diagnosed in about 28% of biopsies prompted by microcalcifications on digital mammography, compared with about 14% on the older film-based systems.⁵ In other words, better imaging technology has made this already-common finding show up on pathology reports more often than it used to.

Is Columnar Cell Change a Precancer?

This is the question most people have when they see “columnar cell lesion” on a pathology report, and the honest answer is nuanced. Researchers believe columnar cell lesions sit at the very beginning of a pathway that can, in rare cases, lead to low-grade breast cancer. They share certain molecular features with low-grade cancers and are frequently found side by side with them in the same tissue specimens.⁶ But “non-obligate precursor” is the critical phrase: the vast majority of columnar cell lesions never progress to anything worrisome.

The evidence on actual cancer risk helps put this in perspective. A large nested case-control study found that women with columnar cell lesions had a modestly elevated risk of breast cancer compared with women without them, with an odds ratio of about 1.44. However, once researchers adjusted for other benign breast disease features that were also present, that association weakened and was no longer statistically significant.⁷ A separate retrospective cohort study found a similar mild increase in overall cancer risk, with a relative risk of about 1.47, and noted no significant risk difference among the three columnar cell lesion subtypes.⁸

What this means in practical terms is that columnar cell change, by itself, raises your breast cancer risk only a small amount, and that modest increase may be largely explained by other changes that tend to coexist with it rather than by the columnar cells themselves. That is a very different situation from a finding like atypical ductal hyperplasia, which carries a meaningfully higher long-term risk.

What the Molecular Evidence Shows

One reason researchers think columnar cell lesions belong at the start of the low-grade cancer pathway is that they share a specific genetic change with low-grade breast cancers: loss of part of chromosome 16 (the long arm, called 16q). A study using a specialized genetic technique found that about 17% of columnar cell lesions without atypia already carried whole-arm losses of 16q. That proportion climbed to roughly 27% for columnar cell lesions with atypia, 47% for atypical ductal hyperplasia, and 57% for low-grade invasive cancers.⁹ That stepwise increase is compelling evidence for a shared biological pathway, even though most columnar cell lesions stop well short of progressing along it.

Another molecular feature of columnar cell change is a uniform and strong expression of estrogen receptors. In normal breast tissue, only a minority of the lining cells express estrogen receptors. In columnar cell change, virtually all of the tall columnar cells show strong, uniform estrogen receptor positivity.¹⁰ The same pattern holds for progesterone and androgen receptors. One study found that the hormone receptor levels in columnar cell lesions were not significantly different from those in co-existing in situ or invasive cancers, and in cases where the columnar lesion lacked a particular receptor, the adjacent cancer lacked it too.¹¹ That mirror-image receptor profile reinforces the idea that these cells are biologically related to the cancers they sometimes coexist with, even when they are not themselves dangerous.

What Happens After a Biopsy Shows Columnar Cell Change

If your needle biopsy shows columnar cell change or columnar cell hyperplasia without atypia, and the pathology matches what the radiologist expected based on your imaging, no further surgery or excision is generally recommended. The finding is treated as benign.¹² You continue routine screening mammography at whatever interval your doctor recommends for your age and risk profile.

The concept of “upgrade rate” is useful here. An upgrade means that when a larger piece of tissue is surgically removed after a needle biopsy, the pathologist finds something more serious than what the needle biopsy showed. For columnar cell change and hyperplasia without atypia, the upgrade rate to actual malignancy is very low. One pooled analysis found a malignancy underestimation rate of about 1.4% across 141 cases.¹³ That is low enough that most experts consider imaging follow-up sufficient rather than proceeding to surgical excision.

The calculus changes when flat epithelial atypia enters the picture. Because FEA sits further along the spectrum and is more frequently found alongside atypical ductal hyperplasia and low-grade cancers, many institutions have traditionally recommended surgical excision when FEA is found on a needle biopsy. In one series, the overall upgrade rate for FEA was about 9%, but this varied dramatically depending on whether the biopsy had fully removed the area of concern: lesions that were completely removed by vacuum-assisted biopsy had an upgrade rate of only 3%, while partially removed lesions upgraded 20% of the time.¹⁴ That kind of data is starting to support a more selective approach, where patients whose FEA has been completely removed by the biopsy device may be safely monitored rather than sent to surgery.

Long-Term Progression Without Surgery

For women who have a columnar cell lesion diagnosed on needle biopsy and are followed without surgical excision, the long-term data are reassuring. One study tracked 259 women with columnar cell lesions managed with observation alone. Over the follow-up period, about 3.5% developed invasive breast cancer, and of those, roughly half occurred in the opposite breast rather than the same one.¹⁵ The fact that cancers appeared in either breast, not just the one with the columnar cell lesion, suggests that the risk is more of a general marker of breast tissue susceptibility than a direct threat from the specific lesion itself. A major landmark study on benign breast disease broadly found that in the first ten years after an initial biopsy, excess cancers did tend to occur in the same breast, but this pattern was especially driven by women who had atypia.¹⁶ Without atypia, the picture is considerably calmer.

Why Pathologists Sometimes Disagree on the Diagnosis

One underappreciated issue with columnar cell lesions is how difficult they can be to classify reproducibly. A study that tested diagnostic agreement among pathologists found that the reliability of distinguishing columnar cell change from columnar cell change with atypia was the weakest link. Agreement between individual pathologists and a reference diagnosis ranged from moderate to substantial on the first attempt, with kappa values between 0.44 and 0.70. Even after a training session and a second round of review, agreement levels did not dramatically improve, and the lowest concordance continued to be for columnar cell change with cytologic atypia.¹⁷

This matters because the line between “no atypia” and “atypia” is exactly the line that determines whether you might be recommended for surgery versus continued observation. If your biopsy report uses borderline language or if you are told you have flat epithelial atypia, it is entirely reasonable to ask whether a second opinion from a breast-specialized pathologist would be helpful. Many breast centers routinely send challenging cases for review, and a second set of eyes can sometimes result in a reclassification that changes the recommended management.

The Terminology Problem

If you start searching for information about columnar cell change, you may run into a confusing tangle of names. The same or very similar findings have been called blunt duct adenosis, columnar alteration of lobules with prominent apical snouts and secretions (sometimes shortened to CAPSS), enlarged lobular units with columnar alteration, and other variations. Blunt duct adenosis was first described in 1945, and for decades, different pathologists used different terms, sometimes treating the finding as a distinct entity and sometimes treating it as a synonym for columnar cell change.¹⁸

The World Health Organization tried to clean this up. Its 2012 classification treated blunt duct adenosis and columnar cell change as synonyms. The 2019 update went a step further and listed blunt duct adenosis as “not recommended” terminology, but without fully resolving whether it should be considered a distinct entity or simply another name for the same thing. This lingering ambiguity means you may still encounter older terminology on pathology reports, particularly at institutions that have used blunt duct adenosis as a diagnostic term for decades. If you see it, it is worth asking your pathologist to clarify where the finding falls on the current columnar cell lesion classification.

When Columnar Cell Change Coexists With Other Findings

A pathology report rarely shows columnar cell change in perfect isolation. More commonly, it coexists with other benign changes: cyst formation, fibrosis, calcifications, or other forms of benign proliferative disease. The clinical significance of columnar cell change depends heavily on what else is present. When it exists alongside atypical ductal hyperplasia or lobular neoplasia, those other findings typically drive the management plan rather than the columnar cell change itself. One study of excision specimens after needle biopsy found that over half displayed additional findings like flat epithelial atypia, atypical ductal hyperplasia, or lobular neoplasia on the surgical specimen even when the initial biopsy had shown only columnar cell lesions.¹⁹

This is why radiology-pathology concordance matters so much. After a needle biopsy, the radiologist and pathologist compare notes: does the pathology explain the imaging finding that prompted the biopsy? If your mammogram showed a suspicious cluster of microcalcifications and the biopsy shows columnar cell change with exactly the kind of calcifications you would expect from it, that is concordant, and observation is reasonable. If the imaging showed something that columnar cell change does not fully explain, that discordance may prompt further workup even when the biopsy tissue itself looks benign.

Estrogen and What It Might Mean for Prevention

The strong, uniform estrogen receptor expression in columnar cell change has raised a question that researchers are still working through: could anti-estrogen therapies reduce the risk of progression in women with these lesions? This idea is speculative at this point, and no clinical trial has specifically tested chemoprevention for isolated columnar cell change. But the biological logic is there. Drugs that block estrogen signaling are already used to reduce breast cancer risk in women with atypical hyperplasia, and since columnar cell change shares some of the same hormonal sensitivity, some researchers have wondered whether the benefit could extend further down the spectrum. For now, the risk associated with plain columnar cell change is low enough that the side effects of anti-estrogen therapy would outweigh the potential benefit for most women. But in patients who have columnar cell change alongside other high-risk features, the hormonal profile of these lesions is one more piece of the puzzle that informs risk discussions.